Original news and analysis on international IP policy
A new report from UNAIDS shows that antiretroviral therapy is now accessed by 18.2 million people living with HIV, and fewer people are dying from the virus infection. However, there is stalled progress on HIV prevention among adults, and growing antiretroviral drug resistance among people living with HIV over a long time.
A new international alliance to support the United Nations Resolution on Antimicrobial Resistance was launched this week. The Conscience of Antimicrobial Resistance Accountability (CARA) aims to bring together organisations committing to reporting on mutually agreed upon indicators in countries around the world, and to hold the UN and other stakeholders accountable to their commitments.
The Access to Medicine Index 2016 was published today, analysing the top 20 research-based pharmaceutical companies. The index looks at how those companies make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. The index found progress in companies' efforts to improve access but little support for flexibilities enshrined in international trade rules.
A range of practitioners and representatives in the manufacture of medicines, intergovernmental officials, academics and civil society representatives last week gave diverse views on the effectiveness of a waiver to international trade rules intended to ease shipments of affordable medicines to low-income countries.
The World Trade Organization intellectual property committee this week discussed the report of United Nations Secretary General’s High-Level Panel on access to medicines which offered recommendations regarding the use of intellectual property in international trade. Developing countries taking the floor accentuated the use of flexibilities under trade rules, and the World Health Organization gave an overview of how its activities follow the panel's recommendations, and its future projects. Civil society meanwhile criticised the WHO’s decision to dismiss a request by some developing countries to include discussions on the UN report at the next Executive Board Meeting.
Today, the Medicines Patent Pool announced that two generic drug companies applied for the World Health Organization prequalification of an innovative antiretroviral.
Funding, universal health, multisectoral work and access to medicines were among the issues addressed at the recent candidates' forum of the World Health Organization in Geneva as part of the process to choose the next director general of the UN health agency. Candidates spoke on how to fund the organisation in its quest for universal health care and response to emergencies.
A much-anticipated report on progress in global access to essential medicines released today has found that change is needed to the system of paying for research and development, including moving beyond sole reliance on patents to cover R&D costs. It calls for a global R&D policy framework, a possible patent pool for essential medicines, addresses financing issues, and claims to have developed a new cost model. Meanwhile, comments ranged from two ministers from the Netherlands said the system is broken while a leading industry executive criticised it for questioning the patent system.
Daniele Dionisio writes: It is morally mandatory to ensure that lifesaving direct-acting antivirals for hepatitis C treatment become accessible to all those who need them. This requires commitment and coordination by all interested parties to overcome barriers to access.
As the head of the World Health Organization warned of funding shortfalls at this week’s financing dialogue, she also proposed to raise assessed country contributions by 10 percent to help mitigate the situation. However, countries had a different take on the suggestion, which is expected to be further considered in the discussions on the budget for 2018/2019, at the Executive Board meeting in January, and at the annual World Health Assembly next May.